AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7750407
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg immediately, then 25 mg b.i.d. (total amount of 150mg) + misoprostol 600 micrograms
Trial: 7750407
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg in the morning and 25mg in the evening for two days (total amount of 150 mg) + misoprostol 600 micrograms
Trial: 7750407
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg b.i.d. (total amount of 125mg) + misoprostol 400 micrograms
Trial: 30957736
Drug: Present-Centred Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present-Centred Therapy (PCT)
Trial: 15013268
Drug: Clopidogrel pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel pretreatment (300 mg loading dose 24 hours before PCI)
Trial: 10374272
Drug: Nitrendipine treatment
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine treatment group
Trial: 7939508
Drug: Standard CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CPB circuit with a standard heparin dose (300 IU/kg)
Trial: 3064861
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) administered to 188 patients
Trial: 14699304
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg) and 600 mg calcium per day for 2 years
Trial: 14699304
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and 600 mg calcium per day for 2 years
Trial: 8837183
Drug: Spinal Anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Anesthesia (SA) with 3 mL of hyperbaric 0.5% bupivacaine
Trial: 12531808
Drug: Irradiation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation plus G-CSF
Trial: 12531808
Drug: Neither irradiation
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither irradiation nor G-CSF
Trial: 8969721
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate infusion, 25 mg/kg (maximum, 2 gm) for 20 minutes
Trial: 8443401
Drug: Aminoglutethimide (Ag)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day
Trial: 8443401
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate (MPA) 500 mg twice a day
Trial: 15891564
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy
Trial: 6391658
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy plus immunotherapy with PSK
Trial: 31241761
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (live implant insertions)
Trial: 27718784
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (methotrexate, docetaxel, or cetuximab)
Trial: 22238398
Drug: Intraduodenal infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusions of glucose at 1, 2, or 3 kcal/min for 60 minutes
Trial: 19962342
Drug: Ribavirin plus
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin plus supportive treatment (Group A, n=64)
Trial: 19962342
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment only (Group B, n=72)
Trial: 16298651
Drug: No antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibody induction (group 3)
Trial: 16298651
Drug: Daclizumab 1
RxNorm normalized name: daclizumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (group 1)
Trial: 16298651
Drug: Daclizumab 2
RxNorm normalized name: daclizumab 25 MG per 5 ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab 2 mg/kg/dose for 2 doses (group 2)
Trial: 21607554
Drug: Single-agent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent docetaxel
Trial: 12065558
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m² on day 1
Trial: 7611158
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (1.2 g/day) and lovastatin (20 mg/day)
Trial: 10362210
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg/day)
Trial: 7611158
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (1.2 g/day)
Trial: 7611158
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nicotinic acid and lovastatin
Trial: 16911626
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine twice daily at breakfast and dinner
Trial: 16911626
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once daily at dinner time
Trial: 9010943
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch of identical size.
Trial: 9010943
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl patch (50-75 micrograms/h).
Trial: 9010943
Drug: Ketorolac (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (60 mg intramuscularly) administered approximately 20-30 minutes before expected end of surgery.
Trial: 9010943
Drug: Acetaminophen (1,300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,300 mg) administered between ketorolac doses if pain persisted.
Trial: 29722919
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioural therapy (cCBT) program
Trial: 21111980
Drug: Low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5 μg kg(‐1) min(‐1) continuous infusion for 8 hours)
Trial: 21111980
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (HDF, 20 mg/h continuous infusion for 8 hours)
Trial: 21111980
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (HDF)
Trial: 12796139
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 mg)
Trial: 8816577
Drug: Single 150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 150-mg oral dose of fluconazole
Trial: 8816577
Drug: Intravaginal antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal antifungal agents
Trial: 1384305
Drug: 5-hydroxytryptophan (5-HTP)
RxNorm normalized name: 5-hydroxytryptophan (5-HTP) 50 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hydroxytryptophan (5-HTP) 900 mg/d
Trial: 3892151
Drug: Initial 18-week
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial 18-week chemotherapy (vincristine, actinomycin D, cyclophosphamide, adriamycin) followed by local therapy (radical surgery or radiation)
Trial: 3892151
Drug: Tumor volume
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor volume less than 100 ml
Trial: 3892151
Drug: Tumor volume
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor volume greater than or equal to 100 ml
Trial: 25694375
Drug: Trigger point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger point therapy (G-TPT)
Trial: 12297477
Drug: Vit C
RxNorm normalized name: M-Vit Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vit C (300 mg/d) and Vit E (600 mg/d) for 15 days before BMT
Trial: 12297477
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received the same treatment without prior vitamin administration
Trial: 10429748
Drug: Fiber supplement
RxNorm normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber supplement (20 g/d)
Trial: 30898329
Drug: Interactive text
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n = 94)
Trial: 30898329
Drug: Five daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n = 99)
Trial: 30898329
Drug: Weekly self-monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly self-monitoring text message assessment only (AO; n = 93)
Trial: 23792179
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) and Antidepressant Medication (ADM)
Trial: 8142205
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide
Trial: 18299686
Drug: Combined angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined angiotensin and angiotensin receptor blockade
Trial: 18299686
Drug: Novel treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatment options
Trial: 15096068
Drug: Smoking reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking reduction during the treatment intervention
Trial: 3140748
Drug: Praziquantel (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (split doses)
Trial: 3140748
Drug: Oxamniquine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxamniquine (single dose)
Trial: 25792830
Drug: Nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (125 mg/m², days 1, 8, and 15) and carboplatin (AUC=2; days 1, 8, and 15) every 21 days for four cycles
Trial: 25792830
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m², days 1, 8, and 15) and carboplatin every 21 days for four cycles
Trial: 9755356
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of selective serotonin reuptake inhibitors with other serotonergic agents
Trial: 8091931
Drug: Vaxigrip vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxigrip vaccine (containing antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88)
Trial: 16438370
Drug: Vaxigrip vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaxigrip vaccine
Trial: 3291008
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy and radiotherapy (Arm B)
Trial: 3291008
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by radiotherapy (Arm A)
Trial: 28193657
Drug: Velpatasvir (VEL)
DrugBank: Velpatasvir (DB11613)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Velpatasvir (VEL) administered at doses up to 450 mg
Trial: 28193657
Drug: Velpatasvir (VEL)
DrugBank: Velpatasvir (DB11613)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Velpatasvir (VEL) at doses greater than 5 mg
Trial: 22011694
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg once daily (QD) after breakfast for 14 days
Trial: 22011694
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg once daily (QD) after breakfast for 14 days
Trial: 22011694
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg twice a day (b.i.d) after breakfast and dinner for 14 days
Trial: 14753248
Drug: Budesonide HFA
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide HFA 400 microg twice daily
Trial: 137218
Drug: Fenoterol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.4 mg)
Trial: 29913280
Drug: Emricasan (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emricasan (25 mg, twice daily for 3 months)
Trial: 26331434
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT) combined with intravenous patient-controlled sufentanil analgesia
Trial: 19138370
Drug: Topical alprostadil
RxNorm normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical alprostadil cream
Trial: 17006735
Drug: Sonographic gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographic gel application (Group A)
Trial: 24255769
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen
Trial: 25943647
Drug: 400 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 µg Folic Acid (FA) daily for a median of 23 days
Trial: 20451683
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor
Trial: 10791109
Drug: IL-4 soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-4 soluble receptor (IL-4sR)
Trial: 10791109
Drug: Other soluble
RxNorm normalized name: others
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other soluble cytokine receptors (IL-6sR, IL-1 beta, TNF-alpha, IL-1sR2, TNF-sR1, TNF-sR2)
Trial: 9340503
Drug: Reteplase (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reteplase (10 MU in two bolus doses given 30 minutes apart)
Trial: 9340503
Drug: Alteplase (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (up to 100 mg infused over a period of 90 minutes)
Trial: 20472116
Drug: celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celecoxib 400 mg orally
Trial: 20705373
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA 1 g daily
Trial: 26368562
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation in LGIB patients
Trial: 20720348
Drug: Sibutramine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine plus L-carnitine
Trial: 17631452
Drug: Cardiac cell
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac cell therapy
Trial: 15153208
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine (Group L, n = 10)
Trial: 9482768
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g maltitol in chocolate
Trial: 9482768
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g maltitol in chocolate
Trial: 2686416
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 g intravenously every eight hours
Trial: 31334795
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment group (n=581) - continuous intravenous insulin targeting blood glucose concentration of 80-130 mg/dL (4.4-7.2 mmol/L)
Trial: 31334795
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (n=570) - insulin on a sliding scale targeting blood glucose concentration of 80-179 mg/dL (4.4-9.9 mmol/L)
Trial: 28911684
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 2 capsules daily for 12 weeks)
Trial: 17602064
Drug: Darbepoetin treatment
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin treatment
Trial: 17602064
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sTfR after 2 weeks and hemoglobin after 4 weeks
Trial: 14988450
Drug: 500 micro
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micro g FA capsule
Trial: 14988450
Drug: 500 micro
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micro g [6S]-5-MTHF capsule
Trial: 30294552
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily insulin injections (MDI)
Trial: 25406267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of treadmill and lower-limb resistance supervised exercise training for 12 weeks
Trial: 16785375
Drug: Methyl aminolevulinate
RxNorm normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyl aminolevulinate PDT (160 mg/g; n = 96)
Trial: 16785375
Drug: Fluorouracil (5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil (5% cream; n = 30)
Trial: 10519330
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) + GnRH analogue
Trial: 6754328
Drug: Factor XIII
RxNorm normalized name: Factor XIII
DrugBank: Factor XIII (human) (DB12909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor XIII treatment
Trial: 6754328
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no factor XIII treatment)
Trial: 30153598
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg ketamine
Trial: 30670277
Drug: Ginger (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (300 mg)
Trial: 30670277
Drug: Frankincense (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frankincense (300 mg)
Trial: 12823598
Drug: Interferon-alpha combined
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha combined with ketoprofen (3 million units three times a week and 150 mg twice a day)
Trial: 9607830
Drug: nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nelfinavir mesylate (750 mg and 1000 mg three times daily)
Trial: 15566422
Drug: Propranolol 160
RxNorm normalized name: propranolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 160 mg daily for 14 days
Trial: 7691342
Drug: Incidental teaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incidental teaching procedures; utilized in a multiple-baseline fashion across three sequential environments.
Trial: 3084952
Drug: Uncooked cornstarch
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncooked cornstarch (1.4-2.0 g/kg body weight, two doses)
Trial: 3084952
Drug: Uncooked cornstarch
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncooked cornstarch (two doses in the morning)
Trial: 3084952
Drug: Uncooked cornstarch
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncooked cornstarch (2-3 g/kg body weight every 6 hours)
Trial: 29146124
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg
Trial: 22301107
Drug: Non-drug-releasing implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug-releasing implants